SAN DIEGO , Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026 . Details of the presentation can be found below. Format: Fireside Chat Presenter: Mani Mohindru, PhD (President and CEO) Date: November 16, 2026 Time: 2:40 PM GMT Interested parties can register for and access the live webcast for the conference by visiting the “ Events ” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation. About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Cardiff’s lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated mCRC, addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients. For more information, please visit https://www.cardiffoncology.com. Investor Contact: Candice Masse Astr Partners candice.masse@astrpartners.com Media Contact: Amy BonannoLyra Strategic Advisory abonanno@lyraadvisory.com Source: Cardiff Oncology, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.